Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration

European Journal of Human Genetics

Volumn 21, Issue 10, 2013, Pages 1152-1157

  Ardeljan, Daniel ^a   Meyerle, Catherine B ^a   Agron, Elvira ^a   Jin Wang, Jie ^b   Mitchell, Paul ^b   Chew, Emily Y ^a   Zhao, Jing ^a   Maminishkis, Arvydas ^a   Chan, Chi Chao ^a   Tuo, Jingsheng ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Age Related Eye Diseases Study; age related macular degeneration; Blue Mountains Eye Study; phenotype; single nucleotide polymorphism; TIMP3

Indexed keywords

MESSENGER RNA; SYNAPSIN; SYNAPSIN III; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; GEOGRAPHIC ATROPHY; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GEOGRAPHIC ATROPHY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PIGMENT EPITHELIUM OF EYE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SYNAPSINS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; WET MACULAR DEGENERATION;

EID: 84884673865     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.14     Document Type: Article

References (31)

1. Friedman DS, O'Colmain BJ, Munoz B et al: Prevalence of age-related macular degeneration in the USA. Arch Ophthalmol 2004; 122: 564-572
2. Age-Related Eye Disease Study Research G. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Agerelated eye disease study report number 3. Ophthalmology 2000; 107: 2224-2232
3. Age-Related Eye Disease Study Research G. A randomized placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-1436
4. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III: Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112: 533-539
5. Evans JR, Fletcher AE, Wormald RP: 28,000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the UK may be attributable to smoking. Br J Ophthalmol 2005; 89: 550-553
6. Hyman L, Neborsky R: Risk factors for age-related macular degeneration: An update. Curr Opin Ophthalmol 2002; 13: 171-175
7. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2008; 28: 1-18
8. Chen W, Stambolian D, Edwards AO et al: Genetic variants near TIMP3 and highdensity lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci USA 2010; 107: 7401-7406
9. Yu Y, Bhangale TR, Fagerness J et al: Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet 2011; 20: 3699-3709
10. Andreoli MT, Morrison MA, Kim BJ et al: Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. Am J Ophthalmol 2009; 148: 869-874
11. Dewan A, Liu M, Hartman S et al: HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314: 989-992
12. Macgregor AM, Eberhart CG, Fraig M, Lu J, Halushka MK: Tissue inhibitor of matrix metalloproteinase-3 levels in the extracellular matrix of lung, kidney, and eye increase with age. J Histochem Cytochem 2009; 57: 207-213
13. Kamei M, Hollyfield JG: TIMP-3 in Bruch's membrane: Changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 2367-2375
14. Qi JH, Ebrahem Q, Moore N et al: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-415
15. Davis MD, Gangnon RE, Lee LY et al: The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123: 1484-1498
16. Attebo K, Mitchell P, Smith W: Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 357-364
17. Mitchell P, Smith W, Attebo K, Wang JJ: Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-1460
18. Ross RJ, Bojanowski CM, Wang JJ et al: The LOC387715 polymorphism and agerelated macular degeneration: Replication in three case-control samples. Invest Ophthalmol Vis Sci 2007; 48: 1128-1132
19. Maminishkis A, Chen S, Jalickee S et al: Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci 2006; 47: 3612-3624
20. Dudbridge F, Koeleman BP: Efficient computation of significance levels for multiple associations in large studies of correlated data, including genomewide association studies. Am J Hum Genet 2004; 75: 424-435
21. Fariss RN, Apte SS, Olsen BR, Iwata K, Milam AH: Tissue inhibitor of metalloproteinases- 3 is a component of Bruch's membrane of the eye. AmJPathol 1997; 150: 323-328
22. Della NG, Campochiaro PA, Zack DJ: Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1996; 37: 1921-1924
23. Weber BH, Vogt G, Wolz W, Ives EJ, Ewing CC: Sorsby's fundus dystrophy is genetically linked to chromosome 22q13-qter. Nat Genet 1994; 7: 158-161
24. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U: Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994; 8: 352-356
25. Felbor U, Stohr H, Amann T, Schonherr U, Weber BH: A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. Hum Mol Genet 1995; 4: 2415-2416
26. Felbor U, Stohr H, Amann T, Schonherr U, Apfelstedt-Sylla E, Weber BH: A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy. J Med Genet 1996; 33: 233-236
27. Fariss RN, Apte SS, Luthert PJ, Bird AC, Milam AH: Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol 1998; 82: 1329-1334
28. Li Z, Clarke MP, Barker MD, McKie N: TIMP3 mutation in Sorsby's fundus dystrophy: Molecular insights. Expert Rev Mol Med 2005; 7: 1-15
29. Xu P, Liu J, Sakaki-Yumoto M, Derynck R: TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Science Signaling 2012; 5: Ra34
30. Dridi S, Hirano Y, Tarallo V et al: ERK1/2 activation is a therapeutic target in age-related macular degeneration. Proc Natl Acad Sci USA 2012; 109: 13781-13786
31. Brew K, Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803: 55-71